Deletion of interleukin-6 alleviated interstitial fibrosis in streptozotocin-induced diabetic cardiomyopathy of mice through affecting TGFβ1 and miR-29 pathways

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhang, Yang ^a   Wang, Jing Hao ^a   Zhang, Yi Yuan ^a   Wang, Ying Zhe ^a   Zhao, Yue ^a   Jin, Xue Xin ^a   Xue, Gen Long ^a   Li, Peng Hui ^a   Sun, Yi Lin ^a   Huang, Qi He ^a   Song, Xiao Tong ^a   Zhang, Zhi Ren ^a   Gao, Xu ^a   Yang, Bao Feng ^a,b   Du, Zhi Min ^a   Pan, Zhen Wei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INTERLEUKIN 6; MICRORNA; MIRN29 MICRORNA, MOUSE; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; BLOOD; C57BL MOUSE; CARDIAC MUSCLE; CELL CULTURE; CELL PROLIFERATION; CHEMICALLY INDUCED; CYTOLOGY; DIABETIC CARDIOMYOPATHY; DIAGNOSTIC IMAGING; DRUG EFFECTS; ECHOCARDIOGRAPHY; FIBROBLAST; FIBROSIS; GENE EXPRESSION; GENETICS; HEART; KNOCKOUT MOUSE; MALE; METABOLISM; NEWBORN; PATHOLOGY; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; DIABETIC CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FIBROBLASTS; FIBROSIS; GENE EXPRESSION; GLUCOSE; HEART; INTERLEUKIN-6; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; MYOCARDIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84960977368     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23010     Document Type: Article

References (28)

1. Pappachan, J. M., Varughese, G. I., Sriraman, R. & Arunagirinathan, G. Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management. World J Diabetes 4, 177-189 (2013).
2. Galderisi, M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol 48, 1548-1551 (2006).
3. Goyal, B. R. & Mehta, A. A. Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion. Hum Exp Toxicol 32, 571-590 (2013).
4. Li, Z., Abdullah, C. S. & Jin, Z. Q. Inhibition of PKC-theta preserves cardiac function and reduces fibrosis in streptozotocin-induced diabetic cardiomyopathy. Br J Pharmacol 171, 2913-2924 (2014).
5. Wang, W. K. et al. Inhibition of high-mobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy. Int J Cardiol 172, 202-212 (2014).
6. Venkatachalam, K. et al. WISP1, a pro-mitogenic, pro-survival factor, mediates tumor necrosis factor-alpha (TNF-alpha)-stimulated cardiac fibroblast proliferation but inhibits TNF-alpha-induced cardiomyocyte death. J Biol Chem 284, 14414-14427 (2009).
7. Sarkar, S., Vellaichamy, E., Young, D. & Sen, S. Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: role of myocytes. Am J Physiol Heart Circ Physiol 287, H107-117 (2004).
8. Melendez, G. C. et al. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 56, 225-231 (2010).
9. Gonzalez, G. E. et al. Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension. J Hypertens 33, 144-152 (2014).
10. Wu, G., Huang, Z. P. & Wang, D. Z. MicroRNAs in cardiac regeneration and cardiovascular disease. Sci China Life Sci 56, 907-913 (2013).
11. Pan, Z. W., Lu, Y. J. & Yang, B. F. MicroRNAs: a novel class of potential therapeutic targets for cardiovascular diseases. Acta Pharmacol Sin 31, 1-9 (2010).
12. Thum, T. et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984 (2008).
13. Wang, J. et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med 16, 2150-2160 (2012).
14. van Rooij, E. et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 105, 13027-13032 (2008).
15. Deten, A., Volz, H. C., Briest, W. & Zimmer, H. G. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res 55, 329-340 (2002).
16. Sarojini, A., Sai Ravi Shanker, A. & Anitha, M. Inflammatory Markers-Serum Level of C-Reactive Protein, Tumor Necrotic Factoralpha, and Interleukin-6 as Predictors of Outcome for Peripartum Cardiomyopathy. J Obstet Gynaecol India 63, 234-239 (2013).
17. Wu, C. K. et al. Plasma levels of tumor necrosis factor-alpha and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase. Crit Care Med 39, 984-992 (2011).
18. Pickup, J. C., Mattock, M. B., Chusney, G. D. & Burt, D. NIDDM as a disease of the innate immune system: association of acutephase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40, 1286-1292 (1997).
19. McGinnis, G. R. et al. Interleukin-6 mediates exercise preconditioning against myocardial ischemia reperfusion injury. Am J Physiol Heart Circ Physiol 308, H1423-1433 (2015).
20. Smart, N. et al. IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res 69, 164-177 (2006).
21. Dawn, B. et al. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res 64, 61-71 (2004).
22. Fuchs, M. et al. Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB J 17, 2118-2120 (2003).
23. Pan, Z. et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 126, 840-850 (2012).
24. Zhang, Y. et al. miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-beta/Smad3 signaling. Mol Ther 22, 974-985 (2014).
25. Qin, W. et al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 22, 1462-1474 (2011).
26. Zhou, L. et al. Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts. Plos One 7, e33766 (2012).
27. Arnold, N., Koppula, P. R., Gul, R., Luck, C. & Pulakat, L. Regulation of cardiac expression of the diabetic marker microRNA miR-29. Plos One 9, e103284 (2014).
28. Kurtz, C. L. et al. MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. Diabetes 63, 3141-3148 (2014).